Representative Portfolio Companies

CellSeed Inc.

【JASDAQ Growth: 7776】
http://www.cellseed.com/index-e.html

Location

Tokyo

Business

Unprecedented cell sheet technology producing regenerative medicine products for a variety of tissues including cornea replacement, cardiac patch, esophageal lining replacement, cartilage sheet and periodontal membrane. Completed a clinical trial for the regenerative cornea product in Lyon, France.

Chiome Bioscience Inc.

【TSE Mothers: 4583】
http://www.chiome.co.jp/english/

Location

Tokyo

Business

Unprecedented cell and molecular biology-based technology enabling discovery and optimization of monoclonal antibodies. Succeeded in generation of monoclonal antibodies against native multiple-trans-membrane proteins. Alliance with Chugai Pharmaceuticals (a Roche Group company), GlaxoSmithKline and Fujirebio.

Japan Medical Information Research Institute, Inc.

【Acquired by INTAGE, Inc.】

Location

Tokyo

Business

Information service providing prescription data, analyses and consultation to pharmaceutical companies operating in Japan.

ProbeX, Inc.

【Acquired by Carna Biosciences, Inc.】
http://www.probex.jp/english/index.html

Location

Tokyo

Business

Proprietary molecular imaging technology for drug discovery. Conducting collaborations with a US-based instrument company and a Japanese reagent company

GreenPeptide Co., Ltd.

http://www.green-peptide.com/english/index.php

Location

Kurume, Fukuoka

Business

Proprietary technology platform enabling personalized peptide vaccines for a variety of cancers and hepatitis C. Completed phase I/II trials for advanced hormone-refractory prostate cancer and malignant brain tumor in Japan. The peptide vaccines were approved for limited therapeutic use for advanced hormone-refractory prostate cancer at Kurume University by MHLW in May 2010.

Page Top